Pulse Biosciences Surpasses 200-Day Moving Average, Signaling Positive Outlook for PLSE
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 18 2025
0mins
Source: NASDAQ.COM
52 Week Range: PLSE's stock has a 52-week low of $13.7658 and a high of $25, with the last trade recorded at $18.01.
Market Analysis: The article suggests checking other stocks that have recently crossed above their 200-day moving average for further investment insights.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on PLSE
Wall Street analysts forecast PLSE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PLSE is 22.00 USD with a low forecast of 22.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 13.550
Low
22.00
Averages
22.00
High
22.00
Current: 13.550
Low
22.00
Averages
22.00
High
22.00
About PLSE
Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s CellFX Nanosecond Pulsed-Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. It is pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation (AF) and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation. Its nsPFA Percutaneous Electrode System consists of a disposable, percutaneous, needle electrode for use with its CellFX Console. Its surgical cardiac ablation clamp is designed for use by cardiac surgeons during the surgical treatment of AF. The CellFX Console is a tunable, software-enabled, console-based platform, designed to accommodate the clinical workflow preferred by physicians. It is also developing a Nanosecond PFA 360-degree Cardiac Catheter System.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pulse Biosciences to Present at 2026 J.P. Morgan Healthcare Conference
- Conference Participation: Pulse Biosciences is scheduled to present on January 14, 2026, at the J.P. Morgan Healthcare Conference in San Francisco, showcasing its innovative nPulse™ technology, which is expected to attract attention from investors and the healthcare industry, thereby enhancing the company's visibility in the bioelectric medicine sector.
- Technology Introduction: The company leverages its proprietary Nanosecond Pulsed Field Ablation (nsPFA™) technology to non-thermally clear cells while sparing adjacent noncellular tissue, demonstrating its potential in treating atrial fibrillation and possibly improving patients' quality of life significantly.
- Market Prospects: Pulse Biosciences is actively pursuing the development of its nPulse technology for use in atrial fibrillation and other markets, which, if successful, could lead to substantial health improvements for both healthcare providers and patients, further driving the company's strategic growth in medical innovation.
- Investor Relations: The company will provide a live and recorded webcast of the presentation on its investor website, enhancing interaction with investors and increasing transparency, which may attract more investor interest and trust.
Continue Reading
Pulse Biosciences (PLSE): Evaluating Valuation Following FDA IDE Approval for nPulse Cardiac Ablation Study
Regulatory Approval: Pulse Biosciences received FDA approval for its nPulse Cardiac Catheter Ablation System, which has positively impacted its stock price, showing a 17.29% return over the past month.
Valuation Concerns: Despite a strong three-year total shareholder return of over 500%, Pulse Biosciences is considered overvalued with a price-to-book ratio of 11.2, significantly higher than industry peers.
Market Sentiment: The current high valuation reflects market optimism about future growth potential, but ongoing losses and potential setbacks could reverse this positive sentiment.
Investment Opportunities: The article suggests exploring other healthcare stocks and highlights various investment themes, including penny stocks and dividend stocks, for potential growth and income strategies.
Continue Reading